Glycated Chitosan Viscosity Reduction for Injectable Therapeutics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional glycated chitosan preparations are difficult to inject and dispense due to high viscosity, making them unsuitable for biomedical applications, and are challenging to sterile filter, rendering them unsuitable for industrial manufacturing and human use.
Innovation Solution
Development of viscoelastic glycated chitosan preparations with controlled molecular weight, degree of deacetylation, and glycation, which improves injectability, reduces viscosity, and allows for sterile filtration, enabling easier administration and manufacturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional glycated chitosan preparations are used, then significant efficacy as an immunoadjuvant is achieved, but the preparations are very difficult to inject or dispense due to high viscosity
Solution Approach 1:
The patent applies parameter changes by modifying the molecular weight of glycated chitosan from conventional high molecular weight (>1500 kDa) to lower molecular weight (50-1500 kDa). This parameter change reduces viscosity and improves injectability while preserving immunoadjuvant efficacy through controlled molecular weight ranges and degree of glycation (5-50%).
Solution Approach 2:
The patent applies local quality by creating heterogeneous mixtures of glycated chitosan with varying molecular weights and degrees of glycation within the same preparation. This allows different regions of the polymer distribution to contribute differently to both viscosity reduction and immunoadjuvant activity, optimizing both injectability and efficacy.
2Reliability
If conventional glycated chitosan preparations are used, then immunoadjuvant activity is achieved, but they are nearly impossible to sterile filter, rendering them unsuitable for industrial manufacturing
Solution Approach 1:
The patent applies parameter changes by controlling molecular weight (50-1500 kDa) and degree of glycation (5-50%) to achieve a balance where the glycated chitosan maintains sufficient immunoadjuvant activity while having reduced molecular size that allows passage through sterile filters (0.22 µm pore size), enabling cGMP-compliant manufacturing.
Solution Approach 2:
The patent applies partial action by using incomplete glycation (5-50% of amino groups glycated) rather than complete glycation. This partial modification reduces molecular weight and improves filterability while retaining enough functional amino groups to maintain immunoadjuvant activity.
3Reliability
If conventional glycated chitosan preparations are used, then therapeutic efficacy is achieved, but the high viscosity makes them unsuitable for human use
Solution Approach 1:
The patent applies parameter changes by optimizing molecular weight (50-1500 kDa) and degree of glycation (5-50%) to reduce viscosity to clinically acceptable levels while preserving therapeutic efficacy. The lower molecular weight reduces polymer entanglement and viscosity, enabling injection through standard needles and catheters.
Solution Approach 2:
The patent applies dynamics by creating viscoelastic preparations whose flow properties can be adjusted through molecular weight control. The preparations exhibit shear-thinning behavior where viscosity decreases under injection stress, facilitating administration while maintaining stability at rest.
Data Source
AI summary
The present invention relates to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.